Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Reexamination Certificate
2005-12-20
2005-12-20
Lankford, Jr., Leon B. (Department: 1651)
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
C424S085100, C424S085400, C424S085500, C435S325000, C435S375000, C435S377000, C514S002600
Reexamination Certificate
active
06977072
ABSTRACT:
A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naïve T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naïve T-cells and exposing the naïve T-cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T-cells to gain immunization of the T-cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions.
REFERENCES:
patent: 4036953 (1977-07-01), Adam et al.
patent: 4116951 (1978-09-01), Wang
patent: 4353821 (1982-10-01), Birr et al.
patent: 4390623 (1983-06-01), Frabricius et al.
patent: 4439196 (1984-03-01), Higuchi
patent: 4447224 (1984-05-01), DeCant, Jr. et al.
patent: 4447233 (1984-05-01), Mayfield
patent: 4454355 (1984-06-01), Schubert et al.
patent: 4466918 (1984-08-01), Birr et al.
patent: 4470926 (1984-09-01), Birr et al.
patent: 4475196 (1984-10-01), LaZor
patent: 4486194 (1984-12-01), Ferrara
patent: 4487603 (1984-12-01), Harris
patent: 4612365 (1986-09-01), Birr et al.
patent: 4910296 (1990-03-01), Birr et al.
patent: 4925678 (1990-05-01), Ranney
patent: 4959217 (1990-09-01), Sanders et al.
patent: 5100664 (1992-03-01), Doyle et al.
patent: 5167616 (1992-12-01), Haak et al.
patent: 5169383 (1992-12-01), Gyory et al.
patent: 5225182 (1993-07-01), Sharma
patent: 5376369 (1994-12-01), Allison et al.
patent: 5503841 (1996-04-01), Doyle et al.
patent: 5632983 (1997-05-01), Hadden
patent: 5643565 (1997-07-01), Doyle et al.
patent: 5679356 (1997-10-01), Bonnem et al.
patent: 5698194 (1997-12-01), Hadden
patent: 5747024 (1998-05-01), Grabstein et al.
patent: 5800810 (1998-09-01), Doyle et al.
patent: 5849307 (1998-12-01), Metz et al.
patent: 6017537 (2000-01-01), Alexander et al.
patent: 6060068 (2000-05-01), Doyle et al.
Barrera J, Verastegul E, Meneses A, Zinser J, de la Garza J, Hadden JW. “Clinical and pathological responses induced by a neoadjuvant treatment with a cytokine mixture (IRX-2) in oral cavity squamous cell carcinoma of head and neck.” International Journal of Immunorehabilitation, vol. 2, No. 3. pp. 29-32, 2000.
Barrera J, Verastegui E, Meneses A, Zinser J, de la Garza J, Hadden JW. “Clinical and pathological bio-responses induced with a cytokine mixture (IRX-2) in patients with oral cavity squamous cell carcinoma.” Clinical and Applied Immunology Reviews, 1:181-185, 2001.
Cortesina G, DeStefani A, Galcazzi E, Cavallo GP, Jemma C, Giovarelli M, Vai S, Fomi G. “Interleukin-2 Injected Around Tumor-Draining Lymph Nodes in Head and Neck Cancer.” Head & Neck, pp. 125-131, Mar./Apr. 1991.
Goldstein, A. “Vaccine Adjuvant In Immunocompromised Patients.” pp. 47-50.
Hadden JW, Endicott J, Baekey P, Skipper P, Hadden EM. “Interleukins and contrasuppression induce immune regression of head and neck cancer”, Arch otolaryngol Head Neck Surg. 120:395-403, 1994.
Musiani P, DeCampora E, Vatitutti S, Castellino F, Calearo C, Cortesina G, Giovarelli M, Jemma C, DeStefani A, Fomi G. “Effect of Low Doses of Interleukin-2 Injected Perilymphatically and Peritumorally in Patients with Advanced Primary Head and Neck Squamos Cell Carcinoma.” Journal of Biological Response Modifers, 8:571-578, Raven Press, Ltd., New York, 1989.
Webb SR, Cooper MD. “T Cells Can Bind Antigen via Cytophilic IgM Antibody Made by B Cells.” The Journal of Immunology, vol. 111, No. 1, pp. 275-277, Jul. 1973.
Banchereau, et al. “Immunology of Dendritic Cells,” Annu. Rev. Immunol. 2000, 18:767-811.
Albert et al, “letter to nature”, Nature, vol. 392, pp. 86-89, 1998.
Barrera J, Verastegui E, Meneses A, Zinser J, de la Garza J, Hadden JW. “Combination immunotherapy of squamous cell head and neck cancer: A phase II trial”, Arch Otolaryngol Head Neck Surg 126:345-351, 2000.
Bellone et al. “Cancer immunotherapy: synthetic and natural peptides in the balance”, Immunology Today, vol. 20, No. 10, p 457-462, 1999.
Berd D, Mastrangelo MJ. “Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T suppressor function without depletion of the CD8+subset”, Cancer Research 47:3317-3321, 1987.
Berd D. “Low doses of chemotherapy to inhibit suppressor T cells”, Progress in Clin Biol Res 288:449-458, 1989.
Borysiewickz LK, Fiander A, Nimako M., Man, S., Wilkinson, GW., Westmoreland, D., Evans, AS., Adams, M., Stacey, SN., Boursnell, ME., Rutherford, E., Hickling, JK., Inglis, SC. “A recombinant vaccine virus encoding human papilomavirus type 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer”, Lancet 347: 1524-1527, 1996.
Burke and Olson, Methods in Enzymology, vol. 194, “Preparation of Clone Libraries in Yeast Artificial-Chromosome Vectors”, eds. C. Guthrie and G. Fink, Academic Press, Inc., Chap. 17, pp. 251-270, 1991.
Capecchi, MR. “Altering the genome by homologous recombination”, Science 244:1288-1292, 1989.
Cortesina G, DeStefani A, Galcazzi E. “Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low dose but not a high dose of recombinant interlukin 2 injected perilymphactically”, Br J Cancer 69:572-577, 1994.
Cortesina G, DeStefani A, Giovarelli M.,et al. “Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin integted perilymphatically”, Cancer 62:2482-2485, 1998.
Cregg JM, Vedvick TS, Raschke WC. “Recent Advances in the Expression of Foreign Genes inPichia pastoris”, Bio/Technology 11:905-910, 1993.
Davies, NP., Rosewell, IR., Brüggemann, M. “Targeted alterations in yeast artificial chromosomes for interspecies gene transfer”, Nucleic Acids Research, vol. 20, No. 11, pp. 2693-2698, 1992.
Deans JP., Boyd AW., Pilarski LM., Transitions from High to Low Molecular Weight Isoforms of CD45 (T200) Involve Rapid Activation of Alternate mRNA Splicing and Slow Turnover of Surface CD45R, The Journal of Immunology, 143:1233-1238, No. 4, Aug. 15, 1989.
Deans JP., Shaw J., Pearse MJ., Pilarski LM., CD45R as a Primary Signal Transducer Stimulating IL-2 and IL-2R mRNA Synthesis by CD3 4 8 Thymocytes, The Journal of Immunology, 143:2425-2430, No. 8, Oct. 15, 1989.
Dallal, RM., Lotze, MT. The dendritic cell and human cancer vaccines, Current Opinion In Immunology 2000, vol. 12, pp. 583-588.
Dickinson, P., Kimber, WL., Kilanowski, FM., Stevenson, B.J., Porteous, DJ., Dorin, JR. “High frequency gene targeting using insertional vector”, Human Molecular Genetics, vol. 2, No. 8, pp. 1299-1302, 1993.
Duff and Lincoln. “Insertion of a pathogenic mutation into a yeast artificial chromosome containing the human APP gene and expression in ES cells”, Research Advances in Alzheimer's Disease and Related Disorders, 1995.
Gilboa E, Eglitis MA, Kantoff PW, Anderson WF. “Transfer and expression of cloned genes using retroviral vectors”, BioTechniques 4(6):504-512, 1986.
Hadden JW. “T-Cell Adjuvants”, Int. J. Immunopharmac. vol. 16, No. 9, pp. 703-710, 1994.
Hadden JW, Endicott, J, Baekey P, Skipper P, Hadden EM. “Interleukins and contrasuppression induce immune regression of head and neck cancer”, Arch otolaryngol Head Neck Surg. 120:395-403, 1994.
Hadden JW, Shah AR, Sosa M, Hadden EM. “Immunotherapy with natural interleukins and/or Thymosin α1potently augments T lymphocyte responses of hy
IRx Therapeutics, Inc.
Kohn Kenneth I.
Kohn & Associates PLLC
Lankford , Jr. Leon B.
LandOfFree
Vaccine immunotherapy for immune suppressed patients does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccine immunotherapy for immune suppressed patients, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine immunotherapy for immune suppressed patients will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3479595